We are a group of motivated immunologists committed to delivering the power of cytokines to patients.
Founded in 2017 by leading experts in the field of immunotherapy, Anaveon is a biopharmaceutical company that specializes in the development of treatments for diseases with immune system dysfunction.
Our goal is to harness the power of engineered cytokines and develop novel treatments for diseases with high unmet need.
Our approach
We are exploiting the power of cytokines to orchestrate immune responses by using protein engineering to create safe and effective treatments for a variety of serious diseases.
IL-2 Cancer Immunotherapy
Our first program going into clinical trials is ANV419, a selective interleukin-2 (IL-2) receptor agonist – a type of protein that can enhance a patient’s immune system in order to target and defeat tumors.
Our Immunotherapy Pipeline
Our pipeline includes additional programs that leverage targeted cytokines for a range of immune-mediated diseases.
Years of Experience
Million CHF Funding
Growing team
LATEST NEWS
16
December
2021
Anaveon to raise CHF 110 million in oversubscribed Series B financing
Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.
12
November
2021
Anaveon announces poster presentation at the 2021 Society for Immunotherapy of Cancer Annual Meeting
24
June
2021
Anaveon doses first patient in a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors
25
March
2021
Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors
Anaveon today announced that its Clinical Trial Application (CTA) has been accepted by the Spanish Agency of Medicines and Medical Devices (AEMPS) to conduct a Phase I/II study evaluating the safety and clinical activity of its lead product, ANV419, as a monotherapy in advanced solid tumors.
10
November
2020
Anaveon announces presentation at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Anaveon, an immuno-oncology company, today announced that it will present a poster at the Society for Immunotherapy of Cancer’s (SITC) 35th Virtual Annual Meeting being held from Monday, November 9, 2020 to Saturday, November 14, 2020.
6 
Our dedicated team of experts has decades of experience in immunology, oncology and drug design. We use our deep knowledge to deliver novel drugs that address unmet medical needs.
About us
We are committed to developing treatments that benefit patients.
Science
We are developing an IL-2 immunotherapy for cancer.
Team
We are driven by the urgency of patients.
Investors
&
Partners
We are backed by more than 36 million CHF (€34 million) of funding.